Lurbinectedin (Zepzelca) is an important medication for the treatment of small cell lung cancer (SCLC), providing new therapeutic options for patients with advanced disease. The proper acquisition and use of the medication are crucial for treatment efficacy and patient safety.
What are the purchasing channels for Lurbinectedin (Zepzelca)?
Overseas Purchase
Patients may consult and purchase lurbinectedin from hospital pharmacies or licensed pharmacies in countries/regions where the medication is approved for marketing.
Since drug prices may be affected by factors such as regional differences and exchange rate fluctuations, patients should make adequate budgeting and planning before purchase.
Purchase through Medical Service Providers
Patients may consult domestic overseas medical service institutions that collaborate with international pharmacies or pharmaceutical companies.
These institutions typically offer legal import channels and provide professional consultation and guidance.
Precautions for the Use of Lurbinectedin (Zepzelca)
Strictly Adhere to Medication Guidelines
The recommended dosage is 3.2 mg/m², administered as an intravenous infusion once every 21 days, with each infusion lasting 60 minutes, until disease progression or the occurrence of unacceptable toxicity.
Special Considerations During Infusion
Extravasation Risk Prevention: Extravasation may cause tissue necrosis requiring debridement.
Infusion Equipment Selection: The use of a 0.22-micron polyethersulfone (PES) in-line filter is recommended.
Diluent Selection: May be diluted with 0.9% Sodium Chloride Injection or 5% Dextrose Injection.
Dose Adjustments for Patients with Hepatic Impairment
Patients with Moderate Hepatic Impairment: The recommended dosage is 1.6 mg/m².
Patients with Severe Hepatic Impairment: Avoid use. If unavoidable, the dosage is 1.6 mg/m².
Management of Drug Interactions
Avoid concurrent use with strong or moderate CYP3A inhibitors.
If concurrent use is necessary, reduce the lurbinectedin dosage by 50%.
Authenticity Verification of Lurbinectedin (Zepzelca)
Packaging Integrity Check
Supplied as a single-dose vial.
The lyophilized powder is white to off-white in color.
Confirmation of Solution Characteristics
After reconstitution, the solution should be clear, colorless or slightly yellow, with no visible particles.
Monitoring of Therapeutic Response
Administer under the supervision of healthcare professionals, with close monitoring of therapeutic efficacy and adverse reactions.
